# US 2009/0263320 A1 · Peptide-Based Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0263320 A1
- Document ID: US20090263320A1
- Status: Published application
- Kind: A1
- Application number: 11/570,090
- Filed: 2005-06-15
- Published: 2009-10-22
- Earliest claimed: 2000-04-12
- Assignees: Ge Healthcare Limited
- Inventors: Alan Cuthbertson
- Web page: https://patentgrep.com/patent/US20090263320A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 51/082: {the peptide being a RGD-containing peptide}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/02: Linear peptides containing at least one abnormal peptide link
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/70546: {Integrin superfamily}
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.

## Claims

### Claim 1

A compound of general formula (I)
and pharmaceutically acceptable salt thereof
wherein
G represents glycine
D represents aspartic acid
Ra represents —(CH2)n— or —(CH2)n—C6H4— wherein
n represents a positive integer 1 to 10
h represents a positive integer 1 or 2
X1 represents an amino acid residue wherein said amino acid possesses a functional side-chain such as an acid or amine,
X2 and X6 represent independently amino acid residues together forming a disulphide bond,
X3 represents arginine, N-methylarginine or an arginine mimetic,
X4 represents a thiol-containing amino acid residue, and
X5 represents a hydrophobic amino acid or derivatives thereof, and
X7 represents a biomodifier moiety or is absent
at least one of Z1 or Z2 is present and represents an antineoplastic agent, or an imageable moiety and
W1 represents a spacer moiety or is absent

### Claim 2 (depends on 1)

A compound as claimed in claim 1 wherein the imageable moiety is a metal entity M chelated by a chelating agent A1.

### Claim 3 (depends on 1)

A compound as claimed in claim 1 wherein any of the amino acid residues are independently in the D or L conformation.

### Claim 4 (depends on 1)

A compound as claimed in claim 1 wherein Ra represents —(CH2)—.

### Claim 5 (depends on 1)

A compound as claimed in claim 1 wherein X1 represents aspartic acid, glutamic acid, lysine, homolysine or another diaminoalcylic acid or derivatives thereof.

### Claim 6 (depends on 1)

A compound as claimed in claim 1 wherein X2, X4 and X6 independently represent a cysteine or homocysteine residue.

### Claim 7 (depends on 1)

A compound as claimed in claim 1 wherein X3 represents arginine.

### Claim 8 (depends on 1)

Compound as claimed in claim 1 wherein X5 represents a tyrosine, phenylalanine, 3-iodo-tyrosine or naphthylalanine.

### Claim 9 (depends on 1)

A compound as claimed in claim 1 wherein X7 comprises 1-10 units of a monodisperse PEG building block.

### Claim 10 (depends on 1)

A compound as claimed in claim 1 wherein X7 comprises 1-10 units of formula (III)

### Claim 11 (depends on 1)

A compound as claimed in claim 1 wherein X7 represent 1-10 amino acid residues

### Claim 12 (depends on 1)

A compound as claimed in claim 1 wherein X7 comprises one or more of glycine, lysine, aspartic acid or serine residues, preferably glycine.

### Claim 13 (depends on 1)

A compound as claimed in claim 1 wherein A1 is a chelating agent of formula (III)
where:
each R1, R2, R3 and R4 is independently an R group;
each R group is independently H or C1-10 alkyl, C3-10 alkylaryl, C2-10 alkoxyalkyl, C1-10 hydroxyalkyl, C1-100 alkylamine, C1-10 fluoroalkyl, or 2 or more R groups, together with the atoms to which they are attached form a carbocyclic, heterocyclic, saturated or unsaturated ring.

### Claim 14 (depends on 1)

A compound as claimed in claim 1 where Al is a chelating agent of formula (IV)

### Claim 15 (depends on 1)

A compound as claimed in claim 1 wherein M comprises metal radionuclides, paramagnetic metal ions, heavy metal ions or cluster ions.

### Claim 16 (depends on 1)

A compound as claimed in claim 1 wherein M comprises 90Y, 99mTc, 111In, 47Sc, 67Ga, 51Cr, 177mSn, 67Cu, 167Tm, 97Ru, 188Re, 177Lu, 199Au, 203Pb or 141Ce.

### Claim 17 (depends on 1)

A compound as claimed in claim 1 wherein M is 99mTc.

### Claim 18 (depends on 1)

A compound as claimed in claim 1 where Z1 or Z2 is present and represents 18F.

### Claim 19 (depends on 1)

A compound as claimed in claim 1 where Z1 or Z2 is present and represents a fluorescent dye.

### Claim 20 (depends on 1)

A compound as claimed in claim 1 where Z1 or Z2 is present and is an antineoplastic agent.

### Claim 21 (depends on 20)

A compound as claimed in claim 20 where Z1 or Z2 is present and represents cyclophosphamide, chloroambucil, busulphan, methotrexate, cytarabine, fluorouracil, vinblastine, paclitaxel, doxorubicin, daunorubicin, etoposide, teniposide, cisplatin, amsacrine or docetaxel.

### Claim 22 (depends on 1)

A compound as claimed in claim 1 where W1 is glutaric or succinic acid

### Claim 23

A pharmaceutical composition comprising an effective amount of a compound of general formula (I) or a salt thereof, together with one or more pharmaceutically acceptable adjuvants, excipients or diluents for use in enhancing image contrast in in vivo imaging or for treatment of a disease.

### Claim 24 (depends on 1)

The use of a compound as claimed in claim 1 in the preparation of a contrast medium for use in a method of diagnosis involving administering said contrast medium to a human or animal body and generating an image of at least part of said body.

### Claim 25 (depends on 1)

The use of a compound as claimed in claim 1 for the preparation of a medicament for the therapeutic or prophylactic treatment of cancer or a related disease in a human or animal.

### Claim 26 (depends on 1)

A method of generating images of a human or animal body involving administering a contrast agent to said body, and generating an image of at least a part of said body to which said contrast agent has distributed, characterised in that said contrast agent comprises a compound as claimed in claim 1.

### Claim 27 (depends on 1)

A method of generating enhanced images of a human or animal body previously administered with a contrast agent composition comprising a compound as claimed in claim 1, which method comprises generating an image of at least part of said body.

### Claim 28 (depends on 1)

A method of monitoring the effect of treatment of a human or animal body with a drug to combat a condition associated with cancer, said method involving administering to said body a compound or composition as claimed in claim 1 and detecting the uptake of said compound or composition by cell receptors, said administration and detection optionally but preferably being effected repeatedly, e.g. before, during and after treatment with said compound or composition.

### Claim 29 (depends on 1)

A method of treating cancer or a related disease in a human or animal body which comprises the administration of an effective amount of a compound or composition as claimed in claim 1.

### Claim 30 (depends on 1)

A compound as claimed in claim 1 for use as a contrast agent in diagnostic imaging, for the treatment of cancer or for the monitoring of the effect of treatment.
